Clinical Trials Browser

OTHER_GOV × Melanoma × tislelizumab × Clear all

NCT04924413 2024-07-03

L-TIL Plus Tislelizumab as First-line Treatment in Advanced Malignant Melanoma

Phase 2 Terminated

Melanoma